News

Filter

Current filters:

Bosulif

Negative NICE appraisal of Pfizer’s Bosulif for CML

Negative NICE appraisal of Pfizer’s Bosulif for CML

27-11-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has issued final guidance…

BosulifEuropeOncologyPfizerPharmaceuticalPricingRare diseasesRegulation

Regulator backs Inlyta, Lucentis and Xtandi for NHS Scotland, but not Bosulif

12-11-2013

The Scottish Medicines Consortium (SMC) revealed this morning (November 12) that it has accepted US drug…

Astellas PharmaBosulifEuropeInlytaLucentisNovartisOncologyOphthalmicsPfizerPharmaceuticalRegulationXtandi

Negative NICE news for Pfizer leukemia drug

16-07-2013

There was disappointment for global drugs behemoth Pfizer (NYSE: OFE) when the UK drugs watchdog the…

BosulifEuropeOncologyPfizerPharmaceuticalPricingRegulation

Conditional EU approval for Pfizer's CML drug Bosulif

28-03-2013

The European Commission has granted conditional marketing authorization for US drugs behemoth Pfizer's…

BiotechnologyBosulifEuropeOncologyPfizerPharmaceuticalRegulation

Good EMA news for Pfizer's Bosulif but not for Santhera's Raxone

21-01-2013

Following its monthly meetings last week, the European Medicines Agency the Committee for Medicinal Products…

BiotechnologyBosulifEuropeOncologyOphthalmicsPfizerPharmaceuticalRaxoneRegulationSanthera Pharmaceuticals

FDA nod for Pfizer's rare leukemia drug Bosulif

06-09-2012

In a third cancer drug approval in just over a year for drugs behemoth Pfizer (NYSE: PFE), the US Food…

BosulifbosutinibNorth AmericaOncologyPfizerPharmaceuticalRare diseasesRegulation

COMPANY SPOTLIGHT

Menarini

Back to top